Evidence map›Paper›PMID 37880426›Full record

ArticleInflammation2024

EGR1 Mediated Reduction of Fibroblast Secreted-TGF-β1 Exacerbated CD8

Rong Jin, Hao Xu, Miaoni Zhou, Fuquan Lin, Wen Xu, Aie Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rong Jin *Department of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Hao Xu *Department of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Miaoni ZhouDepartment of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Fuquan LinDepartment of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Wen XuDepartment of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Aie XuDepartment of Dermatology, Hangzhou Third People's Hospital, 38 Xihu Ave, Hangzhou, Zhejiang Province 310009, People's Republic of China. xuaiehz@msn.com.
Third People's Hospital of Hangzhou · CN

Funding

National Natural Science Foundation of China 82003322National Natural Science Foundation of China Joint Fund Project U22A20310Natural Science Foundation of Zhejiang Province LY21H110002Zhejiang Science and Technology Plan of Traditional Chinese Medicine 2021ZQ075
6 · The paper itself

Abstract

Vitiligo is a T cell-mediated depigment skin disease caused by the complex interplay between melanocyte dysfunction, environmental stimulation, and dysregulated immune signals. Transforming growth factor-β1 (TGF-β1), which typically derives from regulatory T cells, has long been identified at low levels in the peripheral system of vitiligo patients. Here, through RNA-sequencing and transcription factor enrichment, we revealed that in response to CD8

Indexed as

CD8-Positive T-LymphocytesEarly Growth Response Protein 1FibroblastsTransforming Growth Factor beta1VitiligoCell MovementHumansInflammationInterferon-gammaEarly Growth Response Protein 1EGR1 protein, humanInterferon-gammaTGFB1 protein, humanTransforming Growth Factor beta1CD8+ TEGR1FibroblastTGF-β1Vitiligo

Identifiers

PMID37880426
OpenAlexW4387948394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.